Blog Post

Artificial intelligence is rapidly transforming healthcare, reshaping how data is analyzed, diagnoses are made, and treatments are delivered. Among the companies driving this transformation, Tempus AI has emerged as a clear leader by strategically acquiring organizations that expand its technological depth, data assets, and clinical reach. Recent acquisitions — including Paige, a pioneer in digital pathology, Deep 6 AI, a specialist in clinical trial recruitment, and Ambry Genetics, a leader in genomic testing — mark a decisive step forward in Tempus’ mission to advance precision medicine. These moves not only strengthen Tempus’ AI capabilities but also highlight how data-driven innovation can accelerate healthcare breakthroughs and, ultimately, improve patient outcomes across the globe.

Strategic Rationale: Building Superior AI and Data Infrastructure

Paige — Digital Pathology Reinvented

In August 2025, Tempus announced the $81.25 million acquisition of Paige, a leader in digital pathology. This deal brings nearly 7 million de-identified, clinically annotated pathology slide images from 45 countries into Tempus’s ecosystem, along with the first FDA-cleared AI tool in pathology and a groundbreaking million-slide cancer foundation model. The addition of Paige’s deep generative AI expertise and diverse dataset is a critical catalyst as Tempus aims to build the largest oncology foundation model in the world [Zacks].

Deep 6 AI — Accelerating Clinical Trials

Earlier, in March 2025, Tempus acquired Deep 6 AI—an AI-driven precision clinical trial recruitment platform—enhancing its outreach to over 750 provider sites and 30 million patient records. This bolstered use of AI in trial matching (through tools like TIME) and patient care optimization (via Next) represents a meaningful expansion of Tempus’s operational scope [BBAE].

Ambry Genetics — Enabling Genomic Expansion

In late 2024, Tempus completed a $600 million acquisition of Ambry Genetics (part cash, part stock), officially closing in early 2025. This move reinforced Tempus’s genetic testing capabilities in areas such as hereditary cancer screening and expanded its reach into pediatrics, women’s health, rare disease, immunology, and cardiology.

Strategic Impacts: Why These Moves Matter

1. Unmatched Data Scale & Diversity

By combining Paige’s expansive pathology image library, Deep 6’s clinical trial capabilities, and Ambry’s genetic testing services, Tempus now commands one of the most comprehensive multimodal datasets in healthcare. This positions the company to train deeply rich and innovative AI models.

2. Enhanced AI Model Ecosystem

Tempus’s Tempus One platform leverages generative AI to make sense of complex multimodal healthcare data, enabling features like patient trial matching, clinical timelines, and research insights from unstructured notes [Complete AI Training]. With Paige now part of the ecosystem, Tempus can significantly escalate its oncology AI model development.

3. Broader Clinical & Research Reach

These acquisitions open doors into new patient populations, diagnostic mediums, and therapeutic areas. Ambry offers deeper access in genetics; Deep 6 AI connects Tempus to trial-level decision-making; and Paige enhances diagnostic pathology intelligence.

4. Global & Market Leadership

Tempus’s moves signal intent to lead AI healthcare. External investors are taking notice: Lingotto Innovation identifies Tempus AI among its “extreme winners,” highlighting its growing reach among oncologists and data-rich infrastructure [SwingTradeBot]. Earlier, investors like J.P. Morgan and Bank of America expressed bullish sentiment on Tempus’s positioning in AI-enabled personalized medicine.

Conclusion

Tempus AI’s acquisitions of Paige, Deep 6 AI, and Ambry Genetics are more than transactions—they are strategic investments into high-quality data, AI competency, and clinical reach. Together, they position Tempus as a dominant force in AI-powered precision healthcare, with potential implications far beyond the U.S., particularly for healthcare systems in the Global South.